Severe irinotecan-induced toxicity is associated with UGT1A1 polymorphisms. However, some patients develop side-effects despite harbouring a normal UGT1A1 genotype. As CYP3A4 is also an irinotecan-metabolizing enzyme, our study aimed to elucidate the influence of the CYP3A4*20 loss-of-function allele in the toxicity profile of these patients. Three-hundred and eight metastatic colorectal cancer patients treated with an irinotecan-containing chemotherapy were studied. The presence of CYP3A4*20, UGT1A1*37 and UGT1A1*28 alleles was tested. Associations between these genetic variants and toxicity were evaluated. UGT1A1*28 was significantly associated with severe diarrhoea, neutropenia and asthenia (P = 0.002, P = 0.037 and P = 0.041, respectively). One patient with the UGT1A1*28/*37 genotype presented with grade IV neutropenia and lethal septic shock. One heterozygous UGT1A1 (*1/*28) patient also carried the CYP3A4*20 allele but did not develop toxicity. We confirm that UGT1A1*37 and UGT1A1*28 are associated with severe toxicity and suggest that the CYP3A4*20 allele does not play a role in irinotecan-induced toxicity.
Introduction
Irinotecan [also known as camptothecin-11 (CPT-11)] is an active drug that is widely used for the treatment of several types of cancer, including colorectal, gastric and pancreatic cancer. Its dose-limiting and potentially life-threatening toxicities are delayed diarrhoea and severe neutropenia, which can occur in up to 36% of patients [1] .
Several enzymes are involved in the metabolism of irinotecan, highlighting the UDP-glucuronosyltransferase (UGT) isoform 1A1, encoded by the UGT1A1 gene. The number of TA repeats in its TATA box is associated with the enzyme activity. Whereas six TA repeats imply normal activity (UGT1A1*1), seven TA repeats (UGT1A1*28) or eight TA repeats (UGT1A1*37) reduce activity markedly. The UGT1A1*28 allele is strongly associated with irinotecaninduced toxicity [2] [3] [4] . The UGT1A1*37 allele is rare in the Caucasian population [5] , and its influence on irinotecan toxicity has not yet been reported. However, some patients carrying a normal UGT1A1 genotype (*1/*1) develop severe diarrhoea and/or neutropenia. Identification of additional toxicity biomarkers that could help to individualize irinotecan treatment is therefore of major clinical interest in the management of cancer patients.
The enzyme cytochrome P450 3A4 (CYP3A4) converts irinotecan into several inactive oxidation products, such as 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin (NPC). Although the CYP3A4 phenotype is associated with irinotecan pharmacokinetics [6, 7] , no significant associations between CYP3A4 genotype and irinotecan toxicity have been found [8] . Three CYP3A4 nonfunctional alleles result from premature stop codons in the coding gene *6, *20 and *26 CYP3A4 alleles. In Caucasians, these variants are extremely rare, but a frequency of 1.2% of carriers of CYP3A4*20 has recently been reported in the Spanish population as the result of a founder effect [9] .
This state of knowledge prompted us to evaluate whether the presence of the CYP3A4*20 allele could help to identify patients who develop severe irinotecan-induced toxicity despite having a normal UGT1A1 genotype. We genotyped the UGT1A1 (TA repeats) and the CYP3A4*20 variant in a cohort of 308 metastatic colorectal cancer (mCRC) patients treated with an irinotecan-containing therapy.
Methods

Patient population
The study included 308 mCRC patients treated with an irinotecan-containing therapy at Hospital de la Santa Creu i Sant Pau (HSCSP, Barcelona, Spain). Genomic DNA was available in all cases. Left colon cancer was diagnosed in 144 patients, right colon cancer in 76 and rectum cancer in 88. A total of 283 patients received irinotecan combined with fluorouracil and leucovorin (FOLFIRI), 176 of whom were enrolled in clinical trials [10, 11] . The remaining patients received either irinotecan monotherapy or another chemotherapeutic regimen containing irinotecan. Patients were administered chemotherapy until unacceptable toxicity or disease progression. Table 1 shows patients' baseline clinical characteristics.
Relevant clinical data (gender, age and line of chemotherapy) were collected retrospectively through chart review. Toxicity was graded according to the common toxicity criteria (CTC) v4.0: presence and grade of diarrhoea, neutropenia, febrile neutropenia, asthenia, nausea and mucositis. The most severe grade of toxicity was recorded in all cases. The study was approved by the Institutional Ethics Committee at HSCSP, and all study participants gave informed consent to participate.
Genotyping of UGT1A1 and CYP3A4
UGT1A1 genotyping was performed as previously described [10] . CYP3A4*20 (rs67666821) genotyping was carried out by automatic sequencing of a fragment of 244 base pairs in exon 13, which was specifically amplified using the primers FW (5 0 -TGAAGGAGTGTCTCACTC-3 0 ) and RV (5 0 -AGGTCT CTGGTGTTCTCAG-3 0 ).
Statistical analyses
Allele frequencies were calculated by direct counting. The associations between the toxicities assessed and the aforementioned genetic variants were analysed using chi-square tests. The results were considered statistically significant if P <0.05.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [12] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [13] .
Results
A total of 137 of the 308 patients developed some type of grade III/IV toxicity. The most common severe adverse effects observed were neutropenia (68 patients, 22%), asthenia (65 patients, 21%) and diarrhoea (55 patients, 18%). Twentyseven patients experienced severe nausea, nine patients presented with severe mucositis, eight patients experienced febrile neutropenia and two developed septic shock. The frequencies of the genetic variants studied were consistent with Hardy-Weinberg equilibrium. For the UGT1A1 variants, we found 44.2% (*1/*1), 46.4% (*1/*28), 9.1% (*28/*28) and 0.3% (*28/*37). The allelic frequency of UGT1A1*28 was 32%, within the range reported in Spanish populations [14] . The genotype frequencies for the CYP3A4*20 variant were 99.7% (*1/*1) and 0.3% (*1/*20).
There was a clear association between the UGT1A1*28/ *28 genotype and the occurrence of severe diarrhoea (P = 0.002), neutropenia (P = 0.037) and asthenia (P = 0.041) ( Table 2 ). The presence of nausea or mucositis was not 
Discussion
We investigated the role of the CYP3A4*20 allele in mCRC patients with a normal UGT1A1 genotype treated with an irinotecan-containing regimen. We found that UGT1A1*37 and UGT1A1*28 alleles were highly associated with severe toxicity to irinotecan treatment, whereas the presence of the CYP3A4*20 allele was not associated with toxicity in our sample.
Patients harbouring the UGT1A1*28/*28 genotype (Gilbert's syndrome) are at risk of severe irinotecan-induced toxicity [2, 4] . Our findings confirmed this association, as the presence of this genotype was statistically significant for diarrhoea, neutropenia and asthenia (P = 0.002, P = 0.037 and P = 0.041, respectively). One patient who carried the infrequent UGT1A1*28/*37 genotype developed fatal toxicity, despite the reduced doses of irinotecan administered. One explanation for this could be that the additive effect of the UGT1A1*37 allele reduces enzyme activity even more than the UGT1A1*28 allele [15] . This case study reinforces the clinical relevance of identifying such a low-frequency nonfunctional variant before prescribing irinotecan. However, further studies are needed in order to confirm the role of this genetic variant in severe irinotecan-induced toxicity.
Several phenotypic studies have focused on the role of the enzymatic activity of CYP3A4 in irinotecan-induced toxicity. In 2008, Rouits et al. [16] estimated CYP3A4 activity from cortisol biotransformation into 6β-hydroxycortisol. They found that the level of cortisol 6β-hydroxylation predicted the occurrence of diarrhoea. Later, in 2010, van der Bol et al. [17] conducted a randomized trial in which an irinotecan dose of 350 mg m À2 was administered in the control group, whereas the dose was calculated using an algorithm that considered midazolam clearance in the experimental group. They found a significant reduction in the incidence of grades III-IV neutropenia in the experimental group but no differences in grades III-IV diarrhoea [17] . Recently, Makihara et al. [18] conducted a study to evaluate the influence of concomitant use of clarithromycin, a potent CYP3A4 inhibitor, on irinotecan toxicity. The study did not identify an increase in irinotecan-induced toxicity by coadministration of clarithromycin [18] . To the best of our knowledge, to date, only one genotypic study, performed in 177 Japanese cancer patients, has evaluated the influence of variants in the CYP3A4 gene on irinotecan-induced toxicity; no significant association was found [8] .
Recently, a frequency of 1.2% of the loss-of-function CYP3A4*20 allele was described in a Spanish population [9] . In the light of these data, and taking into account the role of CYP3A4 in the metabolism of irinotecan, we hypothesized that the presence of the CYP3A4*20 allele could help to identify patients who will develop severe irinotecan-induced toxicity despite having a normal UGT1A1 genotype. We found one patient carrying the CYP3A4*20 allele (0.3%), a frequency similar to that found in a previous study recently performed by our group [19] and lower than that reported previously by Apellániz-Ruiz et al. [9] . The only patient in our cohort who carried the CYP3A4*20 variant was also heterozygous (*1/*28) for UGT1A1. She did not experience any of the toxicities evaluated in our study. Our findings add uncertainty about the effect of a loss-of-function CYP3A4 allele on severe irinotecan-induced toxicity.
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